JP2024509332A - 多重特異性抗ＴＣＲδ可変部１抗体 - Google Patents

多重特異性抗ＴＣＲδ可変部１抗体 Download PDF

Info

Publication number
JP2024509332A
JP2024509332A JP2023573494A JP2023573494A JP2024509332A JP 2024509332 A JP2024509332 A JP 2024509332A JP 2023573494 A JP2023573494 A JP 2023573494A JP 2023573494 A JP2023573494 A JP 2023573494A JP 2024509332 A JP2024509332 A JP 2024509332A
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509332A5 (https=
Inventor
チュナ，ミフリバン
ウーデン，マーク
フリードマン，ジョシュア
マウント，ナタリー
Original Assignee
ガンマデルタ セラピューティクス リミテッド
エフ－スター セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2111685.0A external-priority patent/GB202111685D0/en
Application filed by ガンマデルタ セラピューティクス リミテッド, エフ－スター セラピューティクス リミテッド filed Critical ガンマデルタ セラピューティクス リミテッド
Priority claimed from PCT/EP2022/054011 external-priority patent/WO2022175414A1/en
Publication of JP2024509332A publication Critical patent/JP2024509332A/ja
Publication of JP2024509332A5 publication Critical patent/JP2024509332A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023573494A 2021-02-17 2022-02-17 多重特異性抗ＴＣＲδ可変部１抗体 Pending JP2024509332A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GB2102224.9 2021-02-17
GB2111685.0 2021-08-14
GBGB2111685.0A GB202111685D0 (en) 2021-08-14 2021-08-14 Anti-tcr delta variable 1 antibodies
PCT/EP2022/054011 WO2022175414A1 (en) 2021-02-17 2022-02-17 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
JP2024509332A true JP2024509332A (ja) 2024-02-29
JP2024509332A5 JP2024509332A5 (https=) 2025-02-26

Family

ID=87849871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573494A Pending JP2024509332A (ja) 2021-02-17 2022-02-17 多重特異性抗ＴＣＲδ可変部１抗体

Country Status (12)

Country Link
US (2) US12312408B2 (https=)
EP (1) EP4294529A1 (https=)
JP (1) JP2024509332A (https=)
KR (1) KR20230160254A (https=)
AU (1) AU2022222299A1 (https=)
BR (1) BR112023016587A2 (https=)
CO (1) CO2023011973A2 (https=)
IL (1) IL305266A (https=)
MX (1) MX2023009544A (https=)
PE (1) PE20240591A1 (https=)
PH (1) PH12023552264A1 (https=)
ZA (1) ZA202308120B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
MX2023009544A (es) * 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528048A (ja) * 2016-07-19 2019-10-10 エフ−スター ベータ リミテッド Ｅｇｆｒ結合分子
WO2020154548A2 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
GB202002581D0 (en) 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
MX2023009544A (es) * 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528048A (ja) * 2016-07-19 2019-10-10 エフ−スター ベータ リミテッド Ｅｇｆｒ結合分子
WO2020154548A2 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY, vol. Vol. 7:e1375641, JPN6026004398, 2017, pages 1 - 14, ISSN: 0005787985 *

Also Published As

Publication number Publication date
KR20230160254A (ko) 2023-11-23
BR112023016587A2 (pt) 2024-01-23
IL305266A (en) 2023-10-01
US20240132599A1 (en) 2024-04-25
ZA202308120B (en) 2024-12-18
CO2023011973A2 (es) 2023-12-20
US20240376215A1 (en) 2024-11-14
PH12023552264A1 (en) 2024-04-22
US12312408B2 (en) 2025-05-27
EP4294529A1 (en) 2023-12-27
MX2023009544A (es) 2023-11-28
AU2022222299A1 (en) 2023-09-07
PE20240591A1 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
JP2025160218A (ja) 抗ｔｃｒデルタ可変１抗体の治療的使用
WO2022175414A9 (en) Multispecific anti-tcr delta variable 1 antibodies
US20220306739A1 (en) Materials and methods for modulating an immune response
JP7847579B2 (ja) 多特異性抗ｔｃｒデルタ可変１抗体
US20210284731A1 (en) Methods and materials for modulating an immune response
US20240376215A1 (en) Multispecific anti-tcr delta variable 1 antibodies
TW202342536A (zh) 多特異性抗ＴＣＲδ可變１抗體
CN117999282A (zh) 抗TCRδ可变1抗体
EA051895B1 (ru) Полиспецифические антитела к вариабельному домену дельта-цепи 1 tcr
HK40109256A (zh) 多特异性抗TCRδ可变1抗体
CN118234754A (zh) 多特异性抗TCRδ可变1抗体
JP2025540777A (ja) イヌのｃｄ３及びｃｄ２０に対する二重特異性抗体
HK40092859A (zh) 多特异性抗TCR δ可变1抗体
HK40104904A (zh) 抗TCRδ可变1抗体
HK40102396A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40097714A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103226A (en) Multispecific anti-tcr delta variable 1 antibodies
EP4110390A1 (en) Materials and methods for modulating an immune response

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203